REPCF(REPCF)
REPCF
10/12/26
RepliCel Life Sciences (REPCF)
Monday
2:26 PM
ThesisRecent clinical trial setbacks and lack of new partnerships have led to increased skepticism among investors regarding the company's growth prospects.
Revenue Outlook
What Moves the Stock
- 01Clinical trial results for RCT-01 and RCT-02
- 02Partnership announcements for commercialization
- 03Regulatory approvals from health authorities
- 04Market adoption rates in key geographies
- 05Regenerative medicine therapies (100%)
- 06Regenerative medicine advancements
- 07Increased focus on personalized healthcare solutions
FY2025 Snapshot
- Revenue
- $353.4K
- Rev. Growth
- -0.1%
- Gross Margin
- 0.0%
- Op. Margin
- 67.3%
- Net Margin
- -114%
- Net Income
- $-401.6K
- NI Growth
- -313%
- EPS
- $-0.01
- 1Y Return
- +0.0%
REPCF Chart
My Notes
- "Investors are increasingly cautious as the timeline for product commercialization extends."
- Moat: RepliCel's proprietary technology provides a moderate level of protection against competitors…
- growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
- Minimal impact, as the company is not currently generating significant revenue and relies on equity financing for operations.
- Watch on earnings: Clinical trial enrollment rates, Partnership agreements, Regulatory approval timelines.
One Sentence Summary:
RepliCel Life Sciences: the story is balanced — clinical trial results for rct-01 and rct-02.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers
